Financial News
Articles published by AVROBIO, Inc.
![](https://mms.businesswire.com/media/20240130047688/en/774246/22/AVROBIO_LOGO.jpg)
AVROBIO and Tectonic Therapeutic Announce Merger
January 30, 2024
From AVROBIO, Inc.
Via Business Wire
Tickers
AVRO
![](https://mms.businesswire.com/media/20230712243011/en/774246/22/AVROBIO_LOGO.jpg)
AVROBIO to Explore Strategic Alternatives
July 12, 2023
From AVROBIO, Inc.
Via Business Wire
Tickers
AVRO
![](https://mms.businesswire.com/media/20230612005105/en/774246/22/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20230522005254/en/774246/22/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20230518005344/en/774246/22/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20230511005197/en/774246/22/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20230501005249/en/774246/22/AVROBIO_LOGO.jpg)
AVROBIO Announces Leadership Transition
May 01, 2023
From AVROBIO, Inc.
Via Business Wire
Tickers
AVRO
![](https://mms.businesswire.com/media/20230323005227/en/774246/22/AVROBIO_LOGO.jpg)
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
March 23, 2023
From AVROBIO, Inc.
Via Business Wire
Tickers
AVRO
![](https://mms.businesswire.com/media/20230303005024/en/774246/22/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20230209005192/en/774246/22/AVROBIO_LOGO.jpg)
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023
February 09, 2023
From AVROBIO, Inc.
Via Business Wire
Tickers
AVRO
![](https://mms.businesswire.com/media/20230105005108/en/774246/22/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20221207005211/en/774246/4/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20221117005291/en/774246/4/AVROBIO_LOGO.jpg)
AVROBIO to Share Comprehensive Gaucher Disease Program Update
November 17, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers
AVRO
![](https://mms.businesswire.com/media/20221108005465/en/774246/4/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20221107005224/en/774246/4/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20221103005147/en/774246/4/AVROBIO_LOGO.jpg)
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers
AVRO
![](https://mms.businesswire.com/media/20221027005331/en/774246/4/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20221025005356/en/774246/4/AVROBIO_LOGO.jpg)
AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis
October 25, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers
AVRO
![](https://mms.businesswire.com/media/20221018005509/en/774246/4/AVROBIO_LOGO.jpg)
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
October 18, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers
AVRO
![](https://mms.businesswire.com/media/20221011005461/en/774246/4/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20221006005214/en/774246/4/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20220927005434/en/774246/4/AVROBIO_LOGO.jpg)
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
September 27, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers
AVRO
![](https://mms.businesswire.com/media/20220920005367/en/774246/4/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20220914005543/en/774246/4/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20220908005131/en/774246/4/AVROBIO_LOGO.jpg)
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers
AVRO
![](https://mms.businesswire.com/media/20220831005278/en/774246/4/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20220809005420/en/774246/4/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20220804005218/en/774246/4/AVROBIO_LOGO.jpg)
![](https://mms.businesswire.com/media/20220801005020/en/774246/4/AVROBIO_LOGO.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.